Shuming Nie

Conflict of Interest The authors declare no conflict of interest. Supporting Information Filename Description adfm70088-sup-0001-SuppMat.docx7 MB Supporting Information References 1, , , , , , , Exp. Mol. Med. 2022, 54, 720. 2a) , , JAMA Network Open 2024, 7, 246476; b) , , , , , , , Ann. Surg. Oncol. 2021, 28, 7095; c) , , , , J. Am. Coll. Surg. 2002, 194, 568; d) , , , , , , , , BJS Open 2022, 6, zrac010; e) , , , , , , , , , , , , , , , , , , Ann. Surg. Oncol. 2023, 30, 5051. 3, , , Cancer Res.

Dense-core vesicles (DCVs) are found in various types of cells, such as neurons, pancreatic β- cells, and chromaffin cells. These vesicles release transmitters, peptides, and hormones to regulate diverse functions, such as the stress response, immune response, behavior, and blood glucose levels. In traditional electron microscopy after chemical fixation, it is often reported that the dense cores occupy a portion of the vesicle toward the center and are surrounded by a clear halo.

New evidence suggests that the mechanism of nanoparticle entry into solid tumours may be driven by an active process. This insight paves the way for approaches to enhance the efficiency of nanomedicine delivery by harnessing active transport mechanisms, and encourage researchers to rethink how tumours are treated. Fig. 1: Active and passive mechanisms for in vivo nanoparticle delivery. References 1. Chan, W. C. W. Acc. Chem. Res. 50, 627–632 (2017). 2. Nakamura, H., Jun, F. & Maeda, H. Expert Opin. Drug Deliv.